The role of JAK/STAT signaling pathway and its inhibitors in diseases
[Display omitted] •The manuscript mainly writes the structure of JAKs and STATs.•The regulation mechanism and negative regulators of JAK/STAT signaling pathway.•Some diseases associated with the JAK/STAT pathway and JAKs inhibitors. The JAK/STAT signaling pathway is an universally expressed intracel...
Gespeichert in:
Veröffentlicht in: | International immunopharmacology 2020-03, Vol.80, p.106210-106210, Article 106210 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [Display omitted]
•The manuscript mainly writes the structure of JAKs and STATs.•The regulation mechanism and negative regulators of JAK/STAT signaling pathway.•Some diseases associated with the JAK/STAT pathway and JAKs inhibitors.
The JAK/STAT signaling pathway is an universally expressed intracellular signal transduction pathway and involved in many crucial biological processes, including cell proliferation, differentiation, apoptosis, and immune regulation. It provides a direct mechanism for extracellular factors-regulated gene expression. Current researches on this pathway have been focusing on the inflammatory and neoplastic diseases and related drug.
The mechanism of JAK/STAT signaling is relatively simple. However, the biological consequences of the pathway are complicated due to its crosstalk with other signaling pathways. In addition, there is increasing evidence indicates that the persistent activation of JAK/STAT signaling pathway is closely related to many immune and inflammatory diseases, yet the specific mechanism remains unclear. Therefore, it is necessary to study the detailed mechanisms of JAK/STAT signaling in disease formation to provide critical reference for clinical treatments of the diseases.
In this review, we focus on the structure of JAKs and STATs, the JAK/STAT signaling pathway and its negative regulators, the associated diseases, and the JAK inhibitors for the clinical therapy. |
---|---|
ISSN: | 1567-5769 1878-1705 |
DOI: | 10.1016/j.intimp.2020.106210 |